LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Summary

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding screening.

Timeline

Start

2026-03-26

Primary completion

2030-06

Completion

2031-07

Drugs

Indications